How Long Has Ozempic Been on the Market? The Full Timeline From Approval to Today

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Ozempic was approved by the FDA in December 2017, making it just over 8 years old as of April 2026.
• It was approved for type 2 diabetes initially, with cardiovascular risk reduction added in January 2020 based on the SUSTAIN-6 trial.
• Semaglutide, the active ingredient, was developed at Novo Nordisk and first published in clinical trial form around 2012.
• A higher-dose formulation of semaglutide called Wegovy was approved for chronic weight management in June 2021.
• Long-term safety data now spans more than a decade including pre-approval clinical use.

Direct answer (40-60 words)

Ozempic has been on the US market since December 5, 2017, when the FDA approved it for type 2 diabetes. As of April 2026, it has been commercially available for about 8 years and 4 months. Its active ingredient, semaglutide, was studied in clinical trials starting around 2012.

Table of contents

1. The 30-second answer
2. The full Ozempic timeline
3. The science behind Ozempic before it was approved
4. The original FDA approval in 2017
5. Label expansions since launch
6. The Wegovy connection
7. Why Ozempic became a cultural phenomenon
8. What 8+ years on the market tells us about long-term safety
9. How Ozempic compares to newer medications
10. Where Ozempic stands today
11. FAQ
12. Sources

The full Ozempic timeline

That's the short version. The longer story has more layers, especially around how the medication moved from a niche diabetes drug to a cultural phenomenon.

The science behind Ozempic before it was approved

GLP-1 (glucagon-like peptide-1) was discovered in the 1980s. It's a hormone the gut produces in response to food, signaling the pancreas to release insulin and the brain to register fullness. Researchers recognized early that mimicking GLP-1 might treat diabetes, but native GLP-1 breaks down within minutes of being released.

The first commercial GLP-1 medication was exenatide (Byetta), approved in 2005. It required twice-daily injections. Liraglutide (Victoza) followed in 2010 with once-daily dosing. Both were improvements over native GLP-1 but still inconvenient.

Novo Nordisk scientists developed semaglutide as a longer-acting GLP-1 analog. By modifying the peptide structure and adding a fatty acid chain, they created a molecule that:

• Resists enzymatic degradation by DPP-4
• Binds to albumin in the blood, slowing clearance
• Maintains effective blood levels for about a week per dose

This let them dose once weekly instead of daily, which transformed real-world adherence. The first published Phase 2 trial appeared around 2012, and the SUSTAIN program (SUSTAIN-1 through SUSTAIN-10) provided the bulk of the safety and efficacy data that supported approval.

By the time the FDA reviewed the application in 2017, semaglutide had been studied in roughly 8,000 participants across multiple trials.

The original FDA approval in 2017

The FDA approved Ozempic on December 5, 2017, for the treatment of adults with type 2 diabetes. The approval was based primarily on the SUSTAIN-1 through SUSTAIN-5 trials, which compared semaglutide against placebo and several active comparators.

Key results from those trials:

• HbA1c reductions of 1.4 to 1.8 percentage points compared with placebo
• Weight reduction of 4 to 6 kg in patients with type 2 diabetes (a secondary endpoint)
• Lower hypoglycemia rates than insulin or sulfonylurea comparators
• Manageable gastrointestinal side effects (nausea, diarrhea, vomiting) that mostly resolved within weeks of initiation

The original approved dosing was 0.25 mg weekly for 4 weeks (titration), then 0.5 mg weekly maintenance, with an option to increase to 1.0 mg for additional glycemic control. The 2.0 mg dose was added in 2022 after additional trials.

The drug came to market with a black box warning about thyroid C-cell tumor risk based on rodent studies, although the human relevance of this finding remains debated. The boxed warning persists on the label as of 2026.

Label expansions since launch

Since the 2017 approval, the Ozempic label has been expanded several times:

January 2020: Cardiovascular risk reduction. Based on SUSTAIN-6 and supporting data, the FDA expanded the Ozempic indication to include reducing the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease (Marso et al., NEJM 2016).

2022: Higher-dose option. A 2.0 mg weekly dose was approved for patients needing additional glycemic control beyond the 1.0 mg maintenance dose.

The diabetes-only indication for Ozempic itself has remained narrow. The chronic weight management indication is held by Wegovy, the higher-dose semaglutide formulation, not Ozempic. This distinction matters legally and clinically: providers prescribing Ozempic for weight loss in patients without type 2 diabetes are doing so off-label.

The Wegovy connection

Wegovy is semaglutide at a higher dose (2.4 mg weekly), formulated specifically for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Wegovy was approved June 4, 2021.

The Wegovy approval was based primarily on the STEP trials. STEP 1, published in 2021 in NEJM (Wilding et al.), showed average weight loss of 14.9% with semaglutide 2.4 mg vs 2.4% with placebo over 68 weeks.

In March 2024, the Wegovy label was expanded to include a cardiovascular indication based on the SELECT trial (Lincoff et al., NEJM 2023), which showed a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease over a median 39.8 months of follow-up.

For consumers, the practical distinction is:

• Ozempic: type 2 diabetes (and cardiovascular risk reduction in diabetes)
• Wegovy: chronic weight management (and cardiovascular risk reduction in obesity with heart disease)
• Rybelsus: oral semaglutide tablets for type 2 diabetes

All three contain semaglutide, the same active ingredient, at different doses and in different formulations.

Why Ozempic became a cultural phenomenon

For about three years after launch, Ozempic was a fairly typical diabetes medication, prescribed by endocrinologists and primary care physicians for blood sugar control. The weight loss was a notable secondary benefit but not central to its identity.

That changed in 2022. Several factors converged:

1. Social media discovery. TikTok and Instagram accounts began documenting weight loss on Ozempic, which exposed the drug to people without diabetes.
2. Off-label prescribing increased. Some providers prescribed Ozempic for weight loss while waiting for a dedicated weight-loss approval (Wegovy was already approved but harder to access).
3. Wegovy supply shortages. When Wegovy launched in 2021, manufacturing capacity could not meet demand. Many patients turned to Ozempic as the available alternative.
4. Celebrity disclosures. Public discussions about GLP-1 use among celebrities normalized the conversation.

By 2023, Ozempic prescriptions had grown roughly 9-fold from 2018 levels (US dispensing data, IQVIA). The drug went from niche endocrinology to a household name.

The cultural attention also produced backlash, supply shortages for diabetes patients, and increased scrutiny of the entire GLP-1 category. The market for compounded semaglutide expanded during this period, partly to fill the gap created by Ozempic and Wegovy shortages.

What 8+ years on the market tells us about long-term safety

By April 2026, Ozempic has been in commercial use for over 8 years, with patients on it for the entire duration in many cases. Pre-approval clinical use stretches the real-world experience to about 14 years. What has the longer follow-up shown?

Confirmed long-term findings:

• Sustained glycemic and weight effects over 5+ years in observational data
• Cardiovascular benefit in high-risk patients (SUSTAIN-6, SELECT)
• Gallbladder disease risk modestly elevated (about 1 to 2% absolute increase over years)
• Pancreatitis risk small but real (around 0.2% per year, similar to other GLP-1 medications)
• No conclusive evidence of human thyroid cancer despite the boxed warning

Findings still being studied:

• Long-term effects on muscle mass with extended use
• Discontinuation outcomes (most patients regain weight after stopping; the magnitude has been quantified in trials like STEP 4)
• Effects in pregnancy (not recommended; data still limited)
• Possible effects on alcohol use, gambling behavior, and other "reward" behaviors documented in observational reports

The general signal from 8+ years of postmarket data is that Ozempic's safety profile is consistent with what was seen in clinical trials. No major unexpected adverse effects have emerged at the population level.

How Ozempic compares to newer medications

Since Ozempic launched, several newer GLP-1 and incretin medications have entered the market:

Tirzepatide, the active ingredient in Mounjaro and Zepbound, has shown stronger weight-loss effects than semaglutide in head-to-head and indirect comparisons (SURMOUNT-5 trial published in 2025 showed 20.2% weight loss with tirzepatide vs 13.7% with semaglutide over 72 weeks).

Despite the entry of stronger competitors, Ozempic continues to be heavily prescribed because of provider familiarity, established cardiovascular data, and broad insurance coverage for diabetes indications.

Where Ozempic stands today

As of April 2026:

• Approved for type 2 diabetes and cardiovascular risk reduction in diabetes
• Available in 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg doses
• Manufactured by Novo Nordisk, marketed in the US, EU, Asia, and most major markets
• No generic semaglutide is available in the US (patents expected to expire in early 2030s)
• Compounded semaglutide remains available through 503A and 503B pharmacies under specific regulatory conditions

Ozempic itself remains an active and clinically relevant medication. The story is not over.

For more on how semaglutide compares to tirzepatide, see /articles/comparison/semaglutide-vs-tirzepatide/. For background on what GLP-1 medications do, see /articles/general-glp1/how-glp1-works/.

FAQ

When was Ozempic FDA approved? December 5, 2017. The FDA approved it for the treatment of adults with type 2 diabetes. The approval was based on the SUSTAIN clinical trial program with about 8,000 participants.

How old is Ozempic in 2026? About 8 years and 4 months as of April 2026. It has been commercially available continuously since December 2017.

Who makes Ozempic? Novo Nordisk, a Danish pharmaceutical company. Novo Nordisk also manufactures Wegovy, Rybelsus, and the older Victoza (liraglutide).

Is Ozempic the same as Wegovy? Both contain semaglutide, the same active ingredient. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. They are not interchangeable from a regulatory or insurance standpoint.

Why did Ozempic become so popular for weight loss? The weight-loss effects were noted as a secondary benefit during diabetes use. Social media coverage in 2022 to 2023, combined with Wegovy supply shortages, drove off-label prescribing for weight loss in patients without diabetes.

Has Ozempic always been used for weight loss? No. The original 2017 FDA approval was only for type 2 diabetes. Wegovy (the higher-dose formulation specifically approved for weight management) was not approved until June 2021. Off-label use of Ozempic for weight loss began increasing in 2022.

Is Ozempic available as a generic? Not yet in the US. Patents on semaglutide are expected to begin expiring in the early 2030s. Compounded semaglutide is available under specific regulatory conditions, but it is not the same as a generic.

What was on the market before Ozempic? Earlier GLP-1 medications included Byetta (exenatide, 2005), Victoza (liraglutide, 2010), Bydureon (extended-release exenatide, 2012), and Trulicity (dulaglutide, 2014). Ozempic was the second once-weekly GLP-1 injection on the US market.

How long has semaglutide been studied? Phase 2 clinical trials began around 2012. The full clinical development program ran from roughly 2012 through 2017 in support of the original FDA approval, and additional trials continue today.

Is the long-term safety of Ozempic established? For its primary indication (type 2 diabetes), yes. More than 8 years of postmarket use plus pre-approval data covering an additional 5 to 6 years gives a substantial safety record. Some long-term questions, especially around indefinite use for weight management, are still being studied.

Why is the Ozempic supply unstable? Demand for GLP-1 medications grew faster than manufacturing capacity. Novo Nordisk has invested in expanded production. As of 2026, supply has stabilized for most doses but periodic shortages of specific dose strengths still occur.

How long do most people stay on Ozempic? For type 2 diabetes, the medication is typically considered a long-term therapy, used as long as it is helpful and tolerated. There is no defined endpoint.

Sources

1. US Food and Drug Administration. NDA approval letter for Ozempic (semaglutide). FDA. December 5, 2017.
2. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
3. Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in type 2 diabetes (SUSTAIN-1). Lancet Diabetes Endocrinol. 2017;5:251-260.
4. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
5. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
6. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
7. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
8. Aroda VR, et al. PIONEER 1: efficacy and safety of oral semaglutide. Diabetes Care. 2019;42:1724-1732.
9. Novo Nordisk. Annual report 2023. Novo Nordisk A/S.
10. IQVIA. US dispensed prescription claims for semaglutide and tirzepatide products, 2018 to 2024.
11. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Byetta and Bydureon are registered trademarks of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.